AstraZeneca’s Q3 Earnings Report Shows Pandemic Price Hikes Profitable for Brand Name Drug Maker

A late third-quarter earnings report from brand name drug makers AstraZeneca shows once again that the pandemic has proven hugely profitable for Big Pharma. AstraZeneca followed other Big Pharma giants that performed well in the third quarter of the year after hiking prices on products in their portfolios throughout the pandemic.


The strong earnings report comes as the company has launched a series of price hikes during the pandemic, and has a history of engaging in anti-competitive tactics:


AstraZeneca has a long history of hiking prices on Americans struggling to afford their medications:

Read more on Q3 earnings from Johnson & Johnson and Roche HERE.

Read more on Q3 earnings from Novartis, Merck, GlaxoSmithKline and Bristol-Myers Squibb HERE.

Read more on Q3 earnings from Sanofi, AbbVie, Pfizer and Amgen HERE.

Learn more about market-based solutions to hold Big Pharma accountable and lower prescription drug prices HERE.

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.